Business Context and Reporting Period
This Form 8-K Current Report was filed by Trovagene, Inc. on April 27, 2016, covering events occurring on April 22, 2016, and April 25-26, 2016. The registrant is a Delaware corporation headquartered in San Diego, California. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Board Resignation: Antonius Schuh resigned as a member of the Board of Directors effective April 26, 2016. His term was set to expire on May 17, 2016, and he had not been re-nominated.
- Executive Departure: Matthew Posard, the Company's Chief Commercial Officer, left the Company on April 22, 2016.
- CEO Appointment: The Board appointed Bill Welch as CEO. This appointment was a point of contention cited in Dr. Schuh's resignation.
Management Commentary, Risks, and Contingencies
Dispute Regarding CEO Selection: Dr. Schuh's resignation letter cited the Board's failure to conduct a thorough external search, the hasty appointment of Bill Welch over objections, and the denial of an opportunity to meet with Mr. Welch. The Company explicitly disputes these assertions, stating that numerous candidates were considered, including Mr. Posard, but an agreement could not be reached due to conditions Mr. Posard demanded that the Board believed would adversely affect the Company.
Board Defense: The Board affirmed that Mr. Welch's experience in developing and commercializing diagnostic and therapeutic products qualified him for the role and emphasized their commitment to fiduciary duties.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Dr. Schuh's resignation.
- Confirm the status of the Chief Commercial Officer role following Mr. Posard's departure.
- Review the Company's capital position and cash runway, as this filing does not disclose financial metrics.
- Monitor future filings for details on the external search process for the CEO position and any potential litigation or disputes arising from the resignation.